Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2 0 -deoxycytidine (5-dAzaC) and interferon-c (IFN-c) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-c. Importantly, pretreatment with 5-dAzaC and IFN-c acted in concert to significantly enhance TRAILinduced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-c, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-c at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.
Introduction
Cell death by apoptosis plays an important role in the regulation of various physiological or pathological conditions and has also been implied to mediate therapy-induced cytotoxicity, for example, in response to cytotoxic drug treatment (Hengartner, 2000; Fulda and Debatin, 2004b) . Apoptosis pathways may be initiated through different entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway), resulting in activation of effector caspases (Fulda and Debatin, 2004b) . Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) receptors results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain (FADD) and caspase-8 (Walczak and Krammer, 2000; Ashkenazi, 2002) . Upon recruitment caspase-8 becomes activated, which in turn can result in direct cleavage of effector caspases (Walczak and Krammer, 2000) . A second pathway is initiated at the mitochondrial level. Apoptogenic factors such as cytochrome c, apoptosisinducing factor (AIF), second mitochondria-derived activator of caspase (Smac)/direct IAP binding protein with low pI (DIABLO) or Omi/high temperature requirement protein A2 (HtrA2) are released from mitochondria into the cytosol triggering caspase-3 activation through formation of the cytochrome c/ Apaf-1/caspase-9-containing apoptosome complex (Saelens et al., 2004) . In these cells, caspase-8 is activated downstream of mitochondria promoting further cleavage of effector caspases. Signals originating from the CD95 receptor may be linked to mitochondria by Bid, a BH3 domain-containing protein of the Bcl-2 family that assumes cytochrome c-releasing activity upon cleavage by caspase-8 thereby initiating a mitochondrial amplification loop (Cory and Adams, 2002) . Studies from caspase-8 knockout mice indicate that caspase-8 plays a necessary and non-redundant role in various forms of cell death (Varfolomeev et al., 1998) .
The concept to directly trigger apoptosis in cancer cells by ligation of death receptors at the cell surface has attracted considerable attention in recent years, as these receptors are directly coupled to the cell's intrinsic suicide machinery (Ashkenazi, 2002) . To this end, TRAIL is considered as a prime candidate because of its tumor selectivity (LeBlanc and Ashkenazi, 2003) . However, the potential exploitation of TRAIL for cancer therapy is hampered by the fact that many tumors remain resistant towards TRAIL despite expression of both agonistic TRAIL receptors (LeBlanc and Ashkenazi, 2003) . This non-responsiveness to TRAIL may be caused by the dominance of antiapoptotic programs and/or survival signals or by defects in key components of the cell death machinery (Fulda and Debatin, 2004a) . Recent studies by our group and other investigators have revealed that caspase-8 expression is epigenetically silenced by hypermethylation of a gene regulatory region in many human cancers, including neuroblastoma, medulloblastoma, Ewing tumors, melanoma or small cell lung carcinoma (Grotzer et al., 2000; Hopkins-Donaldson et al., 2000 Teitz et al., 2000; Eggert et al., 2001; Fulda et al., 2001 Fulda et al., , 2002 . Reexpression of caspase-8 by caspase-8 gene transfer or demethylation agents sensitized resistant cancer cells for death receptor or drug-induced apoptosis (HopkinsDonaldson et al., 2000; Teitz et al., 2000; Eggert et al., 2001; Fulda et al., 2001) . In addition, interferon-g (IFNg) upregulated caspase-8 expression through a Stat1/ IRF1-dependent pathway, in line with the notion that the caspase-8 promoter contains IFN-g-responsive elements (Ruiz-Ruiz et al., 2000 Kontny et al., 2001; Banelli et al., 2002; Fulda et al., 2002; Yang et al., 2003; Casciano et al., 2004) . However, the clinical use of demethylating agents or IFN-g may be limited, as high drug concentration found to be active in vitro often cannot be administered in vivo because of toxic side effects (Jonasch and Haluska, 2001; Esteller, 2005) . In this respect, combination regimens may offer the advantage to exploit synergistic interactions of agents at suboptimal individual drug doses to increase the therapeutic efficacy and decrease the toxicity towards the host (Fan et al., 1998) .
In search for novel approaches to re-activate caspase-8 and to overcome intrinsic resistance of cancers, we therefore investigated the effect of combination regimens on caspase-8 expression and TRAIL-induced apoptosis in the present study.
Results
Recent studies demonstrate that treatment with demethylating agents or IFN-g resulted in upregulation of caspase-8 expression in tumor cells, which lack caspase-8 (Hopkins- Donaldson et al., 2000; Grotzer et al., 2000; Ruiz-Ruiz et al. 2000; Teitz et al., 2000; Eggert et al., 2001; Fulda et al., 2001 Fulda et al., , 2002 Yang et al., 2003) . Although these agents have been tested as monotherapy to upregulate caspase-8, the question whether or not their combined use may offer advantages has not yet been addressed. Therefore, we addressed this issue in the present study.
Cooperation of interferon-g and 5-Aza-2 0 -deoxycytidine to restore caspase-8 expression As a model of tumor cells with inactivation of caspase-8, we used the neuroblastoma cell line SH-SY5Y, which we previously found to lack caspase-8 expression . To restore caspase-8, we used different classes of agents known to modulate gene expression, including the demethylating agent 5-Aza-2 0 -deoxycytidine (5-dAzaC), IFN-g and the histone deacetylase inhibitor (HDACI) trichostatin (TSA) (Baylin, 2002; Esteller, 2005) . Treatment of SH-SY5Y neuroblastoma cells with either 5-dAzaC or IFN-g alone resulted in increased caspase-8 protein expression in a dosedependent manner, whereas treatment with subtoxic concentrations of TSA only marginally induced caspase-8 (Figure 1a-c) . Interestingly, we found that simultaneous administration of both 5-dAzaC and IFN-g at relatively low concentrations acted in concert to increase caspase-8 expression (Figure 1d ). Additionally, we tested a combination of 5-dAzaC and TSA, as the combined use of demethylation agents and HDACI has previously been reported to cooperatively re-activate expression of epigenetically silenced genes (Cameron et al., 1999) . However, combined treatment with 5-dAzaC and TSA was less effective to upregulate caspase-8 compared to the combination of 5-dAzaC and IFN-g in SH-SY5Y neuroblastoma cells (Figure 1d and e). To exclude the possibility that the cooperative effect of 5-dAzaC and IFN-g was restricted to a particular cell line, we extended our studies to additional tumor cell lines with inactivation of caspase-8. Similarly, 5-dAzaC and IFN-g acted in concert to upregulate caspase-8 expression in LAN1 and Kelly neuroblastoma cells (Figure 1f and g ). In addition to neuroblastoma, we also included medulloblastoma in our study, which we previously found to lack caspase-8 expression as well (Fulda et al., 2001) . Also in D283Med medulloblastoma cells, 5-dAzaC and IFN-g cooperated to upregulate caspase-8 (Figure 2a-d) indicating that the cooperative interaction of 5-dAzaC and IFN-g was not restricted to a specific tumor type. By comparison, the combined use of 5-dAzaC and TSA was less effective than the combination of 5-dAzaC and IFN-g to upregulate caspase-8 expression also in D283Med medulloblastoma cells ( Figure 2e ). Together, this set of experiments demonstrates that 5-dAzaC and IFN-g cooperated to restore caspase-8 expression in neuroblastoma and medulloblastoma cell lines with low or absent caspase-8.
Restoration of caspase-8 function by re-expression of caspase-8
We then asked whether re-expression of caspase-8 by 5-dAzaC and IFN-g would translate into restoration of caspase-8 function. To address this question, we analysed caspase-8 activity after re-expression of caspase-8 using an enzymatic caspase assay. Pretreatment of SH-SY5Y neuroblastoma cells with 5-dAzaC and IFN-g, which upregulated caspase-8 in these cells (Figure 1d ), resulted in a significant increase in caspase-8 activity upon addition of TRAIL compared to cells that were pretreated with 5-dAzaC alone, IFN-g alone or that received no pretreatment ( Figure 3a) . In addition to caspase-8, activities of caspase-3 and -9 were also significantly enhanced in TRAIL-treated cells that were pretreated with 5-dAzaC and IFN-g (Figure 3b and c). These results demonstrate that restoration of caspase-8 expression by 5-dAzaC and IFN-g also restored caspase-8 function and overcame the blockade in activation of the caspase cascade.
Sensitization for TRAIL-induced apoptosis through re-expression of caspase-8 To investigate whether re-expression of caspase-8 by 5-dAzaC and IFN-g would have an impact on the susceptibility of cells to undergo programmed cell death, we pretreated SH-SY5Y neuroblastoma cells with 5-dAzaC, IFN-g or the combination of 5-dAzaC and IFN-g for 2 days to upregulate caspase-8 protein followed by treatment with TRAIL to trigger apoptosis. Importantly, simultaneous preincubation with 5-dAzaC and IFN-g was significantly more effective to enhance TRAILinduced cytotoxicity compared to cells that were preincubated with 5-dAzaC alone, IFN-g alone or that received no pretreatment (Figure 4 ). Additionally, we determined apoptosis by assessing DNA fragmentation of propidium iodide-stained nuclei. Similarly, combined pretreatment of SH-SY5Y cells with 5-dAzaC and IFNg strongly enhanced TRAIL-induced apoptosis compared to SH-SY5Y cells that received no pretreatment or that were preincubated with either 5-dAzaC or IFN-g alone ( Figure 5 ). These findings corresponded to our results obtained by Western blot, which showed highest caspase-8 protein levels in cells simultaneously treated with 5-dAzaC and IFN-g compared to those incubated with either 5-dAzaC or IFN-g alone (Figure 1d ). Dose response experiments of IFN-g revealed that maximal cooperative activity of IFN-g and 5-dAzaC to sensitize for TRAIL-induced apoptosis was achieved at a concentration of 1000 U/ml IFN-g (Supplementary Figure 1) . To exclude that the observed apoptosis sensitization effect was restricted to a particular cell type such as neuroblastoma, we extended our studies to medulloblastoma cells. Similarly, combined pretreatment Cooperation of 5-dAzaC and IFN-c to upregulate caspase-8 S Fulda and K-M Debatin with 5-dAzaC and IFN-g also significantly increased TRAIL-induced apoptosis in D283Med medulloblastoma cells compared to cells that were preincubated with 5-dAzaC alone, IFN-g alone or that received no pretreatment ( Figure 6 ). Thus, pretreatment with 5-dAzaC and IFN-g sensitized neuroblastoma and medulloblastoma cells for TRAIL-induced apoptosis.
Requirement of caspase-8 for apoptosis sensitization by 5-Aza-2 0 -deoxycytidine and interferon-g Our findings obtained so far suggest that restoration of caspase-8 expression by combined treatment with 5-dAzaC and IFN-g was able to overcome TRAIL resistance of neuroblastoma and medulloblastoma cells. However, as demethylation agents or IFN-g may modulate expression of a variety of genes, we wished to explore the specific contribution of caspase-8. To this end, we monitored the expression of various pro or antiapoptotic regulators of apoptosis by Western blot. Combined incubation with 5-dAzaC and IFN-g slightly enhanced protein expression of caspase-10, whereas no significant alterations in expression levels of caspase-2, -3 or -9, molecules of the death receptor pathway (FLICE inhibitory protein (FLIP), TRAIL), inhibitor of apoptosis proteins (IAPs), Bcl-2 family proteins or ) cooperate to enhance TNF-related apoptosis-inducing ligand (TRAIL)-induced caspase activity. SH-SY5 neuroblastoma cells were left untreated or were pretreated for 48 h with 0.3 mM 5-dAzaC and/or 1000 U/ml IFN-g and then incubated for 24 h in the absence (white bars) or presence (black bars) of 100 ng/ml TRAIL. Activity of caspase-8 (a), caspase-9 (b) or caspase-3 (c) was analysed by enzymatic caspase assay using fluorogenic caspase substrates, and arbitrary units of caspase activity are shown. Mean þ s.d. of three independent experiments performed in triplicate are shown. For statistical analysis, t-test was performed (**Po0.01).
Cooperation of 5-dAzaC and IFN-c to upregulate caspase-8 S Fulda and K-M Debatin HSP70 were observed (Figure 7) . Also, no increase in surface expression of agonist TRAIL receptors was detected as assessed by flow cytometry (data not shown).
To further investigate the specific contribution of caspase-8 to the observed sensitization effect provided by 5-dAzaC and IFN-g, we used a dominant-negative mutant of caspase-8. Importantly, specific inhibition of caspase-8 by dominant-negative caspase-8 also abolished sensitization to TRAIL-induced apoptosis following treatment with 5-dAzaC and IFN-g (Figure 8a ). Furthermore, addition of the relatively specific caspase-8 inhibitor zIETD.fmk blocked the sensitization to TRAIL-induced apoptosis observed in cells pretreated with 5-dAzaC and IFN-g (Figure 8b ). Collectively, these findings demonstrate that interfering with caspase-8 function also inhibited the increase in TRAIL-induced apoptosis provided by 5-dAzaC and IFN-g, pointing to a crucial role of caspase-8 in this sensitization effect.
Discussion
Despite aggressive therapy, poor response of many tumors to current treatment protocols still remains a major concern in oncology. As resistance may be caused by defective cell death programs due to mutations and/ or epigenetic changes, the identification of the underlying molecular mechanisms may be crucial to design novel strategies to overcome the blockade in apoptosis pathways (Baylin, 2002; Johnstone et al., 2002) . Recent evidence indicates that a variety of tumors, including neuroblastoma, medulloblastoma, Ewing tumors, melanoma or small cell lung carcinoma, evade apoptosis by 0 -deoxycytidine (5-dAzaC) and interferon-g (IFN-g) on expression of pro-or antiapoptotic molecules. SH-SY5 neuroblastoma cells were left untreated or were pretreated for 48 h with 0.3 mM 5-dAzaC and/or 1000 U/ml IFN-g and analysed by Western blot for protein expression of caspases-2, -3, -9, -10, FLICE inhibitory protein (FLIP), TNF-related apoptosisinducing ligand (TRAIL), survivin, X-chromosome-linked inhibitor of apoptosis protein (XIAP), cIAP2, Bax, Bcl-2, Bcl-X L , HSP70 and b-actin. In addition to XIAP, a nonspecific XIAP immunereactive molecule migrating slightly faster than XIAP was detected using the mouse monoclonal antibody H62120 (Deveraux and Reed, 1999) , which is indicated by asterisk. 0 -deoxycytidine (5-dAzaC) and interferon-g (IFN-g) cooperate to enhance TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in medulloblastoma cells. D283Med medulloblastoma cells were left untreated or were pretreated for 48 h with 0.1 mM 5-dAzaC and/or 1000 U/ml IFN-g and then incubated for 24 h (a) or 48 h (b) in the absence (white bars) or presence (black bars) of 100 ng/ml TRAIL. Apoptosis was determined by fluorescence-activated cell sorting (FACS) analysis of DNA fragmentation of propidium iodide-stained nuclei. Mean þ s.d. of three independent experiments performed in triplicate are shown. For statistical analysis, t-test was performed (*Po0.05).
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Here, we report that combined treatment with 5-dAzaC and IFN-g at suboptimal individual drug concentrations cooperated to restore caspase-8 expression and function and sensitized resistant neuroblastoma and medulloblastoma cells for TRAIL-induced apoptosis. This conclusion is based on the following independent pieces of evidence: First, simultaneous treatment with 5-dAzaC and IFN-g was more effective to enhance caspase-8 expression compared to either agent alone. Second, re-expression of caspase-8 by pretreatment with 5-dAzaC and IFN-g also restored caspase-8 function, resulting in increased caspase-8 activity upon TRAIL receptor ligation and activation of effector caspases such as caspase-3. Third, restoration of caspase-8 expression and function by pretreatment with 5-dAzaC and IFN-g lowered the threshold for apoptosis induction and sensitized resistant neuroblastoma and medulloblastoma cells for TRAILtriggered apoptosis. Fourth, caspase-8 was required for sensitization to TRAIL provided by 5-dAzaC and IFN-g, as inhibition of caspase-8 activity by ectopic expression of dominant-negative caspase-8 or by addition of the relatively specific caspase-8 inhibitor zIETD.fmk also inhibited this sensitization effect.
Although there are previous reports by our group and other investigators showing that single agent treatment with either 5-dAzaC or IFN-g enhanced caspase-8 expression in tumor cells (Grotzer et al., 2000; Hopkins-Donaldson et al., 2000 Teitz et al., 2000; Eggert et al., 2001; Fulda et al., 2001 Fulda et al., , 2002 Kontny et al. 2001; Banelli et al., 2002; Yang et al., 2003) , the current study presents for the first time evidence that the simultaneous administration of both agents at relatively low individual drug doses cooperates in upregulating caspase-8. The molecular basis of this cooperative interaction of 5-dAzaC and IFN-g may be explained by the different modes of action of each agent to upregulate caspase-8. We previously reported that the demethylating agent 5-dAzaC reversed hypermethylation of a gene regulatory region of the caspase-8 gene (Fulda et al., 2001) , whereas IFN-g enhanced caspase-8 levels through transcriptional activation of caspase-8 through a Stat-1/IRF1-dependent pathway without altering the methylation status of the caspase-8 gene . Thus, our findings indicate that the combination of agents with distinct modes of action to regulate caspase-8 expression can synergize in gene activation. This cooperative interaction occurred in a dose-dependent manner, particularly at suboptimal drug concentrations, whereas it was not observed at doses, that already strongly induced caspase-8 levels . The rationale for combination therapies is based on the concept that combining agents with distinct modes of action at relatively low individual drug doses may offer benefits by increasing the therapeutic efficacy and by decreasing toxicity towards the host (Fan et al., 1998) . Although our data point to a crucial role of caspase-8 in the 5-dAzaC/IFN-g-mediated sensitization to TRAIL, we cannot exclude that the effect of 5-dAzaC and IFN-g on apoptosis modulation may also involve additional molecules. Besides the strong upregulation of caspase-8 by combined treatment with 5-dAzaC and IFN-g, we found a slight increase in caspase-10 expression, whereas no significant alterations in expression levels of caspase-3, -7 or -9, proteins of the Bcl-2 family, IAPs or signaling molecules of the death receptor pathway were detected. However, given the minor upregulation of caspase-10 by 5-dAzaC and IFNg compared to the strong increase in caspase-8 and as our functional analysis clearly demonstrated that caspase-8 was required for the sensitization effect, it appears unlikey that caspase-10 is a major determinant of apoptosis sensitivity under these conditions. This notion is further supported by the fact that the relevance of caspase-10 for TRAIL-induced apoptosis has been controversially discussed (Kischkel et al., 2001; Sprick et al., 2002) .
Caspase-8 is frequently lost in a variety of human cancers (Grotzer et al., 2000; Hopkins-Donaldson et al., 2000 Teitz et al., 2000; Eggert et al., 2001; Fulda et al., 2001; Kontny et al., 2001 ) and has recently been reported to bear prognostic impact in medulloblastoma (Pingoud-Meier et al., 2003) . Thus, our findings may have important clinical implications. Current attempts to improve survival of cancer patients will depend on strategies to target tumor cell resistance to apoptosis, as the efficacy of most anticancer therapies critically depends on intact cell death programs in cancer cells. The death-inducing ligand TRAIL is considered as a promising candidate for cancer therapy, because it almost selectively induces apoptosis in a wide spectrum of cancers by directly engaging the cell's intrinsic death machinery with no or minimal toxicity to normal human cells (LeBlanc and Ashkenazi, 2003) . Agents triggering TRAIL receptors, for example, agonistic TRAIL receptor antibodies or recombinant TRAIL, have been extensively studied in preclinical models and are currently under investigation in clinical trials (LeBlanc and Ashkenazi, 2003) . However, the potential application of TRAIL for cancer therapy is hampered by the fact that many tumors remain resistant towards treatment with TRAIL despite expression of both agonistic TRAIL receptors (LeBlanc and Ashkenazi, 2003) . This may be caused by defects in key components of the TRAIL signaling pathway such as inactivation of caspase-8 (Fulda and Debatin, 2004a) . As the antitumor activity of TRAIL critically depends on the cell's intact apoptotic machinery, the clinical use of TRAIL will require strategies to restore defective apoptosis pathways in cancer cells. Thus, combination regimens to reexpress caspase-8 in cancer cells lacking caspase-8 may prove to be a useful novel approach to enhance the efficacy of TRAIL-based protocols in the treatment of cancer.
Caspase activity Caspase activity was determined by fluorogenic substrates for caspase-3 (Roche Diagnostics), caspase-8 (BioCat GmbH, Palo Alto, CA, USA) or caspase-9 (Bachem) according to the manufacturer's instructions. Caspase activity was measured fluorometrically at 535 or 510 nm on a microplate fluorescence reader using 1420 Victor Multilabel Counter (Perkin-Elmer, Boston, MA, USA).
Transfection experiments SH-SY5Y neuroblastoma cells were transfected with dominant-negative caspase-8 (Fernandes-Alnemri et al., 1996) or empty vector using lipofectamine transfection reagent (Life Technologies Inc.) as previously described (Fulda et al., 2001 ).
Co-transfection with pDsRed1-N1 plasmid (BD Bioscience) was performed for transient transfection to identify transfected cells (>70% transfection efficacy).
